Fil: Starnino, Stefania. Vaccine and Infectious Diseases Organization, University of Saskatchewan, Saskatoon, Saskatchewan; Canada.Fil: Galarza, Patricia. ANLIS Dr.C.G.Malbrán. Instituto Nacional de Enfermedades Infecciosas; Argentina.Fil: Carvallo, María Elena Trigoso. Centro Departamental de Vigilancia, Información y Referencia, La Paz; Bolivia.Fil: Benzaken, Adele Schwartz. Fundção Alfredo da Matta, Manaus – Amazonas; Brasil.Fil: Ballesteros, Aurora Maldonado. Instituto de Salud Publica, Santiago; Chile.Fil: Cruz, Olga Marina Sanabria. Instituto Nacional de Salud, Bogotá; Colombia.Fil: Hernandez, Alina Llop. Instituto de Medicina Tropical “Pedro Kourí”, Ministerio Salud Publica, Habana; Cuba.Fil: Carbajal, José Luis Portilla. Instituto Nacional de Salud, Lima; Perú.Fil: Borthagaray, Graciela. Facultad de Química, Universidad de la Republica, Montevideo; Uruguay.Fil: Payares, Daisy. Instituto Nacional de Higiene “Rafael Rangel” Caracas; Venezuela.Fil: Dillon, Jo-Anne R. Vaccine and Infectious Diseases Organization, University of Saskatchewan, Saskatoon, Saskatchewan; Canada.The emergence of resistance and treatment failures to third generation cephalosporins prompted the revitalization of the global Gonococcal Antimicrobial Surveillance Program (GASP) to ensure that information regarding trends of the antimicrobial susceptibility of Neisseria gonorrhoeae isolates is up-to-date. Accordingly, former and potential GASP participants in Latin America and the Caribbean were contacted to reinitiate the GASP network in the region and to undertake a retrospective analysis of the antimicrobial susceptibility of N. gonorrhoeae isolates between 2000 and 2009.